L-NMMA

Phase 2Small molecule

NNational Heart, Lung, and Blood Institute (NHLBI)

L-NMMA is one of 83 small molecule programs targeting Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerCompleted

LocalCompleted

PembrolizumabActive, not recruiting

Autonomic Nervous SystemCompleted

Breast CancerPhase 2

Completed

LocalPreclinical

Completed

PembrolizumabPhase 1

Active, not recruiting

Autonomic Nervous SystemPreclinical

Completed

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

L-NMMA

NNational Heart, Lung, and Blood Institute (NHLBI)

Phase 2

2 2

Adenocard

Astellas

Preclinical

2 3

Blenoxane

Bristol-Myers Squibb

Preclinical

1 4

Lexiscan

Astellas

Preclinical

1 5

Voltaren

Novartis

Preclinical

1 6

Zolymbus

AbbVie

Preclinical

1 7

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 9

Spravato

WWim Janssens

Preclinical

2 10

Duragesic-100

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Breast Cancer

NCT05660083

Clinical

Trials by Indication[1]

Sickle Cell Disease4 trials

Therapeutic Application of Intravascular Nitrite for Sickle Cell Disease

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 1·NCT00095472·18 enrolled

Atorvastatin Therapy to Improve Endothelial Function in Sickle Cell Disease

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00072826·44 enrolled

Niacin to Improve Blood Flow in People With Sickle Cell Disease

Completed·NNational Heart, Lung, and Blood Institute (NHLBI)·Phase 2·NCT00508989·30 enrolled

Show 1 more trial

Nitric Oxide to Improve Blood Flow in Sickle Cell Disease

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 2·NCT00009581·65 enrolled

Breast Cancer2 trials

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Completed·TThe Methodist Hospital Research Institute·Phase 1/2·NCT02834403·37 enrolled

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

Recruiting·TThe Methodist Hospital Research Institute·Phase 2·NCT05660083·36 enrolled

Completed·RRadboud University Medical Center·Phase 1·NCT00185003·36 enrolled

9 more indications

Sarcopenia1 trial

Insulin and Sarcopenia in the Elderly

Completed·TThe University of Texas Medical Branch, Galveston·Phase 1·NCT00690534·88 enrolled

Growth1 trial

Effect of DPP4 Inhibition on Growth Hormone Secretion

Completed·VVanderbilt University·Phase 4·NCT01701973·44 enrolled

Autonomic Nervous System1 trial

Nitric Oxide and the Autonomic Nervous System

Completed·VVanderbilt University·N/A·NCT00178919·112 enrolled

Pembrolizumab1 trial

Phase Ib of L-NMMA and Pembrolizumab

Active, not recruiting·TThe Methodist Hospital Research Institute·Phase 1·NCT03236935·12 enrolled

Pathophysiology1 trial

Pathophysiology of Cardiometabolic Risk Factors in African Americans

Completed·VVanderbilt University Medical Center·Phase 1·NCT01122407·34 enrolled

Local1 trial

Characterization of Local Vascular Effects of LNMMA

Completed·TTechnische Universität Dresden·N/A·NCT00180063

Obstructive Sleep Apnea1 trial

Renal Hemodynamics and Tubular Function in Patients With Obstructive Sleep Apnea and Healthy Controls

Completed·RRegional Hospital Holstebro·Phase 4·NCT00410085·40 enrolled

MPA1 trial

Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation

Withdrawn·UUniversity of Wisconsin, Madison·Phase 1·NCT03066115

Unspecified1 trial

SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies

Completed·AAmsterdam UMC, location VUmc·Phase 4·NCT01744236·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 18 trial records for L-NMMA. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — L-NMMA compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for L-NMMA. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — National Heart, Lung, and Blood Institute (NHLBI) company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNational Heart, Lung, and Blood Institute (NHLBI)

L-NMMA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Sickle Cell Disease4 trials

Breast Cancer2 trials

Endothelial Function1 trial

Pulmonary Hypertension1 trial

Endotoxemia1 trial

Sarcopenia1 trial

Growth1 trial

Autonomic Nervous System1 trial

Pembrolizumab1 trial

Pathophysiology1 trial

Local1 trial

Obstructive Sleep Apnea1 trial

MPA1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News